Overview
- Servier India announced a biomarker-testing programme that offers a customised panel at subsidised rates across private and government providers.
- IDH1 and IDH2 mutation tests are free for eligible patients when ordered by government doctors, with discounted pricing available in private settings.
- MedGenome and Strand Life Sciences are the named laboratory partners responsible for implementing the initiative across India.
- Results from IDH1/IDH2 testing guide diagnosis, prognosis and treatment choices for AML and cholangiocarcinoma, including eligibility for drugs such as ivosidenib and enasidenib.
- Private testing has typically cost Rs 20,000–50,000 for AML and Rs 70,000–3,00,000 for CCA, while government data cite AML incidence at 2–3 per 100,000 and higher CCA rates in northern states than in the south.